阿司匹林用于超重与肥胖患者翻修髋膝关节置换术后静脉血栓预防安全有效
该回顾性研究纳入1578例连续翻修全髋或全膝关节置换(RTHA/RTKA)病例,按体质指数(BMI)分为正常、超重、肥胖、重度肥胖与病态肥胖五组,评估术后90天静脉血栓栓塞(VTE)、出血、伤口并发症、深部感染与死亡率。结果显示各组VTE及各并发症发生率差异均无统计学意义,提示阿司匹林在肥胖患者中预防VTE安全有效。
要点
- 出血、伤口并发症、感染与死亡率在各BMI组间均无显著差异。
- 阿司匹林(325或81 mg)可用于超重及肥胖患者翻修关节置换术后的VTE预防。
核心结论
- 阿司匹林用于超重及肥胖患者翻修全髋/全膝关节置换术后VTE预防安全有效,并发症发生率与非肥胖患者相似。
研究设计与样本
- 回顾性研究,纳入1578例连续RTHA/RTKA病例(751例RTHA、827例RTKA),患者接受325或81 mg阿司匹林,按BMI分为正常(18-24.9 kg/m2)、超重(25-29.9 kg/m2)、肥胖(30-34.9 kg/m2)、重度肥胖(35-39.9 kg/m2)与病态肥胖(≥40 kg/m2)五组。
主要发现
- 各组例数分别为正常335例、超重511例、肥胖408例、重度肥胖232例、病态肥胖92例。
关键数值与推荐
- VTE定义为肺栓塞或深静脉血栓;术后90天为观察窗。
- 阿司匹林处方剂量为325或81 mg。
- BMI分组界值:正常18-24.9、超重25-29.9、肥胖30-34.9、重度肥胖35-39.9、病态肥胖≥40 kg/m2。
临床怎么用
- 翻修髋膝关节置换术后可考虑用阿司匹林(325或81 mg)预防VTE,超重及肥胖患者无需因BMI而常规排除该方案。
- 用药期间仍需关注出血、伤口并发症与感染风险,但本研究显示各BMI组间这些结局无显著差异。
局限性
- 本研究为回顾性设计,原文摘要未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE), defined as pulmonary embolism or deep venous thrombosis, is a rare but serious complication following revision total hip arthroplasty (RTHA) and revision total knee arthroplasty (RTKA). Previous studies show that obesity may be associated with an increased risk for pulmonary embolism, wound complications, and infection. With no current universal standard of care for VTE prophylaxis, we sought to determine whether aspirin prescribed (ASA) is safe and effective in obese patients undergoing RTHA/RTKA. METHODS: A retrospective review of 1578 consecutive RTHA/RTKA cases (751 RTHAs and 827 RTKAs) was conducted identifying patients prescribed 325 or 81 mg ASA. Ninety-day postoperative VTE rates, bleeding, wound complications, deep infections, and mortality were collected. Cohorts were stratified according to body mass index (BMI): normal (18-24.9 kg/m2), overweight (25-29.9 kg/m2), obese (30-34.9 kg/m2), severely obese (35-39.9 kg/m2), and morbidly obese (≥40 kg/m2). RESULTS: The cohort comprised of 335 patients with a normal BMI, 511 were overweight, 408 obese, 232 severely obese, and 92 morbidly obese. Total VTE rates were statistically similar between BMI groups (0.90% vs 0.78% vs 0.74% vs 0.43% vs 0%, P = .89). There were no differences in bleeding rates (0.90% vs 0% vs 0% vs 0.43% vs 0%, P = .08), wound complications (0.30% vs 0.20% vs 0.25% vs 0% vs 0%, P = .93), infection (1.49% vs 1.57% vs 0.98% vs 1.29% vs 1.09%, P = .66), or mortality (0% vs 0.20% vs 0% vs 0% vs 0%, P = .72). CONCLUSION: ASA is safe and effective for VTE prevention in obese patients with similar complication rates to nonobese patients undergoing RTHA/RTKA.
引用
- Tang A, Sicat CS, Singh V, et al. Aspirin Use for Venous Thromboembolism Prevention Is Safe and Effective in Overweight and Obese Patients Undergoing Revision Total Hip and Knee Arthroplasty. J Arthroplasty. 2020. PMID: 33376036. doi:10.1016/j.arth.2020.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。